Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.

Sellner J, Koczi W, Harrer A, Oppermann K, Obregon-Castrillo E, Pilz G, Wipfler P, Afazel S, Haschke-Becher E, Trinka E, Kraus J.

Clin Exp Immunol. 2013 Sep;173(3):381-9. doi: 10.1111/cei.12125.

2.

Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.

Elovaara I, Ukkonen M, Leppäkynnäs M, Lehtimäki T, Luomala M, Peltola J, Dastidar P.

Arch Neurol. 2000 Apr;57(4):546-51.

PMID:
10768630
3.

Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.

Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.

Mult Scler. 2011 Jan;17(1):16-23. doi: 10.1177/1352458510383075. Epub 2010 Oct 11.

PMID:
20937631
4.

Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.

Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G.

Ann Rheum Dis. 2008 Aug;67(8):1121-6. Epub 2007 Nov 20.

5.

Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity.

Kraus J, Oschmann P, Engelhardt B, Bauer R, Schiel C, Kern A, Stolz E, Traupe A, Dorndorf W.

Acta Neurol Scand. 2000 Feb;101(2):135-9.

PMID:
10685862
6.

Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.

Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, Spitaleri DL, Iuliano G, Tedeschi G, Della Corte M, Bonavita S, Matarese G.

Metabolism. 2015 Sep;64(9):1112-21. doi: 10.1016/j.metabol.2015.05.001. Epub 2015 May 8.

PMID:
25986733
7.

High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.

Harrer A, Pilz G, Wipfler P, Oppermann K, Sellner J, Hitzl W, Haschke-Becher E, Afazel S, Rispens T, van der Kleij D, Trinka E, Kraus J.

Clin Exp Immunol. 2015 Jun;180(3):383-92. doi: 10.1111/cei.12590. Epub 2015 Apr 27.

8.

Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules.

Durán I, Martínez-Cáceres EM, Río J, Barberà N, Marzo ME, Montalban X.

Brain. 1999 Dec;122 ( Pt 12):2297-307.

9.

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T.

PLoS One. 2011;6(9):e24604. doi: 10.1371/journal.pone.0024604. Epub 2011 Sep 16.

10.

Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation.

Rojas B, Cuhna R, Zafirakis P, Ramirez JM, Lizan-garciía M, Zhao T, Foster CS.

Exp Eye Res. 2005 Sep;81(3):313-25.

PMID:
16129099
11.

Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS.

Correale J, Bassani Molinas Mde L.

J Neuroimmunol. 2003 Jul;140(1-2):198-209.

PMID:
12864990
12.

The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis.

Blauth K, Zhang X, Chopra M, Rogan S, Markovic-Plese S.

Clin Immunol. 2015 Apr;157(2):121-32. doi: 10.1016/j.clim.2015.01.001. Epub 2015 Jan 14.

PMID:
25596452
13.

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.

CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. Review.

14.

Phenotyping analysis of peripheral blood leukocytes in patients with multiple sclerosis.

Paź A, Fiszer U, Zaborski J, Korlak J, Członkowski A, Członkowska A.

Eur J Neurol. 1999 May;6(3):347-52.

PMID:
10210917
15.

Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.

Jensen MA, Yanowitch RN, Reder AT, White DM, Arnason BG.

Mult Scler. 2010 Jan;16(1):30-8. doi: 10.1177/1352458509352794. Epub 2009 Dec 9.

PMID:
20007427
16.

Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.

Praksova P, Stourac P, Bednarik J, Vlckova E, Mikulkova Z, Michalek J.

J Neurol Sci. 2012 Aug 15;319(1-2):18-23. doi: 10.1016/j.jns.2012.05.036. Epub 2012 Jun 5.

PMID:
22676847
17.

Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients.

Pul R, Morbiducci F, Škuljec J, Skripuletz T, Singh V, Diederichs U, Garde N, Voss EV, Trebst C, Stangel M.

PLoS One. 2012;7(12):e51867. doi: 10.1371/journal.pone.0051867. Epub 2012 Dec 20.

18.

The effects of Castanospermine, an oligosaccharide processing inhibitor, on mononuclear/endothelial cell binding and the expression of cell adhesion molecules.

Hibberd AD, Trevillian PR, Clark DA, McElduff P, Cowden WB.

Transpl Immunol. 2012 Aug;27(1):39-47. doi: 10.1016/j.trim.2012.05.002. Epub 2012 May 27.

PMID:
22647882
19.

Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS.

Elovaara I, Lällä M, Spåre E, Lehtimäki T, Dastidar P.

Neurology. 1998 Dec;51(6):1703-8.

PMID:
9855526
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk